Patient demographic and clinical characteristics among the 119 HCT recipients
| . | n . | % . |
|---|---|---|
| Age at transplant | ||
| Median, range, y | 60 | 19-76 |
| Race | ||
| Black | 5 | 4.2 |
| Caucasian | 114 | 95.8 |
| Sex | ||
| Female | 51 | 42.86 |
| Male | 68 | 57.14 |
| ABO mismatch | ||
| Yes | 49 | 41.18 |
| No | 69 | 57.98 |
| Unknown | 1 | 0.84 |
| Disease | ||
| Myeloid | 81 | 68.07 |
| Lymphoid | 35 | 29.41 |
| Myeloma | 3 | 2.52 |
| Comorbidity index | ||
| 0 | 18 | 15.13 |
| 1-2 | 44 | 36.97 |
| 3-4 | 41 | 34.45 |
| >4 | 16 | 13.45 |
| Stem cell source | ||
| Cord Blood | 1 | 0.84 |
| Haplo donor | 18 | 15.13 |
| Related | 17 | 14.29 |
| Unrelated | 83 | 69.75 |
| Stem cell product | ||
| Bone marrow | 32 | 26.89 |
| Cord blood | 1 | 0.84 |
| Peripheral blood stem cells | 86 | 72.27 |
| HLA match 8/8 | ||
| No | 22 | 18 |
| Yes | 97 | 82 |
| HLA match 10/10 | ||
| No | 24 | 20 |
| Yes | 95 | 80 |
| Donor/recipient CMV | ||
| Donor positive, recipient positive | 33 | 27.73 |
| Donor negative, recipient positive | 35 | 29.41 |
| Donor positive, recipient negative | 10 | 8.4 |
| Donor negative, recipient negative | 41 | 34.45 |
| Conditioning regimen | ||
| Myeloablative | 59 | 49.58 |
| RIC | 60 | 50.42 |
| GVHD prophylaxis | ||
| FK containing regimens | 104 | 87.39 |
| Siro containing regimens | 3 | 2.52 |
| FK and Siro containing regimens | 7 | 5.88 |
| T-cell depletion | 3 | 2.52 |
| Post-cy alone | 2 | 1.68 |
| . | n . | % . |
|---|---|---|
| Age at transplant | ||
| Median, range, y | 60 | 19-76 |
| Race | ||
| Black | 5 | 4.2 |
| Caucasian | 114 | 95.8 |
| Sex | ||
| Female | 51 | 42.86 |
| Male | 68 | 57.14 |
| ABO mismatch | ||
| Yes | 49 | 41.18 |
| No | 69 | 57.98 |
| Unknown | 1 | 0.84 |
| Disease | ||
| Myeloid | 81 | 68.07 |
| Lymphoid | 35 | 29.41 |
| Myeloma | 3 | 2.52 |
| Comorbidity index | ||
| 0 | 18 | 15.13 |
| 1-2 | 44 | 36.97 |
| 3-4 | 41 | 34.45 |
| >4 | 16 | 13.45 |
| Stem cell source | ||
| Cord Blood | 1 | 0.84 |
| Haplo donor | 18 | 15.13 |
| Related | 17 | 14.29 |
| Unrelated | 83 | 69.75 |
| Stem cell product | ||
| Bone marrow | 32 | 26.89 |
| Cord blood | 1 | 0.84 |
| Peripheral blood stem cells | 86 | 72.27 |
| HLA match 8/8 | ||
| No | 22 | 18 |
| Yes | 97 | 82 |
| HLA match 10/10 | ||
| No | 24 | 20 |
| Yes | 95 | 80 |
| Donor/recipient CMV | ||
| Donor positive, recipient positive | 33 | 27.73 |
| Donor negative, recipient positive | 35 | 29.41 |
| Donor positive, recipient negative | 10 | 8.4 |
| Donor negative, recipient negative | 41 | 34.45 |
| Conditioning regimen | ||
| Myeloablative | 59 | 49.58 |
| RIC | 60 | 50.42 |
| GVHD prophylaxis | ||
| FK containing regimens | 104 | 87.39 |
| Siro containing regimens | 3 | 2.52 |
| FK and Siro containing regimens | 7 | 5.88 |
| T-cell depletion | 3 | 2.52 |
| Post-cy alone | 2 | 1.68 |